Physician profile
Eslin Luka
NPI 1184250987
$11,432.01
in general payments reported to CMS, 2019-2025
55 companies · $2,441 in 2025
The $2,441 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,283 · 2022: $2,324 · 2023: $2,829 · 2024: $2,555 · 2025: $2,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,475 · Education: $200 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,475.00 |
| Education | $199.98 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,258.63 | 2021-2025 | |
| Lilly USA, LLC | $703.10 | 2021-2025 | Emgality, Kisunla, Reyvow |
| Jazz Pharmaceuticals INC. | $644.03 | 2021-2025 | |
| Ucb, INC. | $610.02 | 2021-2025 | Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $585.55 | 2021-2025 | Ajovy |
| Argenx US, INC. | $563.27 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $525.33 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Genentech USA, INC. | $468.69 | 2021-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Celgene Corporation | $331.83 | 2022-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $331.79 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $294.79 | 2022-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $264.35 | 2021-2025 | Hyqvia |
| Eisai INC. | $252.59 | 2023-2025 | |
| Pfizer INC. | $240.26 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $239.26 | 2023-2024 | Aptiom |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $234.25 | 2023-2025 | Wakix |
| Lundbeck LLC | $226.40 | 2022-2025 | Vyepti |
| Merz Pharmaceuticals, LLC | $226.04 | 2021-2024 | Xeomin |
| Biohaven Pharmaceuticals, INC. | $217.47 | 2021 | |
| Tg Therapeutics, INC. | $210.51 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $207.67 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $206.23 | 2023-2025 | Nuplazid, Daybue |
| Amneal Pharmaceuticals LLC | $197.80 | 2021-2024 | Rytary, Crexont |
| Amgen INC. | $176.68 | 2021-2025 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $166.41 | 2021-2025 | Dysport |
| Biohaven Pharmaceutical Holding Company LTD. | $144.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $141.77 | 2022-2024 | Xarelto |
| Genzyme Corporation | $131.95 | 2021-2023 | |
| Kyowa Kirin, INC. | $130.59 | 2021-2023 | Nourianz |
| Averitas Pharma INC. | $128.65 | 2024 | Qutenza |
| Corium, LLC | $111.85 | 2023 | Adlarity |
| Inspire Medical Systems, INC. | $100.31 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $98.86 | 2023-2025 | Sunosi |
| Catalyst Pharmaceuticals, INC. | $91.58 | 2021-2025 | Firdapse |
| Alnylam Pharmaceuticals INC. | $91.03 | 2022-2025 | Onpattro |
| Grifols USA, LLC | $88.55 | 2021-2025 | Gamunex-C |
| Acorda Therapeutics, INC | $86.27 | 2021-2023 | Inbrija |
| Avion Pharmaceuticals | $84.96 | 2021-2022 | |
| Sk Life Science, INC. | $72.03 | 2022-2024 | |
| Allergan, INC. | $69.71 | 2021-2022 | |
| Grt US Holding, INC. | $69.40 | 2022 | |
| Alexion Pharmaceuticals, INC. | $69.02 | 2022-2024 | Ultomiris, Soliris |
| Cycle Pharmaceuticals INC | $59.14 | 2025 | Tascenso Odt, Bafiertam |
| Otsuka America Pharmaceutical, INC. | $35.14 | 2023-2024 | Nuedexta |
| Avadel Cns Pharmaceuticals, LLC | $33.52 | 2024 | Lumryz |
| Janssen Biotech, INC. | $31.48 | 2025 | |
| Ge Healthcare | $31.13 | 2025 | |
| Csl Behring | $27.97 | 2025 | Privigen, Hizentra |
| Emd Serono, INC. | $27.49 | 2023 | Mavenclad |
| Octapharma USA, INC. | $24.67 | 2025 | Panzyga |
| Banner Life Sciences, LLC | $14.83 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.65 | 2023 | Quviviq |
| Scilex Pharmaceuticals INC. | $13.58 | 2024 | |
| Impel Pharmaceuticals INC. | $12.85 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eslin Luka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.